High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease

Narayani Jayakumari, Gopalan Thejaseebai, Narayani Jayakumari, Gopalan Thejaseebai

Abstract

Paraoxonase-1 (PON-1), an HDL-associated enzyme has been shown to possess antioxidant/anti-inflammatory properties and protect against atherogenesis. The aim of the study was to explore the association of PON-1, with lipids, antioxidant-vitamins and lifestyle in male subjects with and without angiographically documented coronary artery disease (CAD) and in healthy volunteers. PON-1 activity was measured spectrophotometrically using phenyl acetate as substrate. PON-1 and HDL-Cholesterol were significantly lower and lipid peroxides and triglycerides were higher in CAD patients than in normal coronary and control subjects. PON-1 activity showed positive association with HDL-C and inverse relation with lipid peroxides and no association with antioxidant vitamins in healthy subjects. Smoking habit, alcohol intake and diabetes mellitus did not seem to influence PON-1 activity. Serum levels of PON-1 and HDL-C showed inverse association with the presence of CAD but are not related to the severity of disease in terms of number of diseased vessels. Interventional means by diet/drugs to enhance PON-1 activity may contribute to attenuation of atherosclerosis.

Keywords: Atherosclerosis; HDL; Oxidativestress; Paraoxonase.

Figures

Fig. 1
Fig. 1
Influence of risk factors such as diabetes mellitus, smoking habit and alcohol intake on (a) PON-1 activity, (b) HDL-cholesterol and (c) lipid peroxides among control subjects.
Fig. 2
Fig. 2
Influence of biochemical variables such as (a) HDL-cholesterol and (b) lipid peroxides on PON-1 activity in tertiles among control subjects.

References

    1. Ross R. Atherosclerosis an inflammatory disease. New Engl. J. Med. 1999;340:115–118.
    1. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Fuall K.F., Fogelman A.M., Navab M. Protective effect of HDL-paraoxonase: inhibition of the biological activity of minimally oxidized LDL. J. Clin. Invest. 1996;96:2882–2891.
    1. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipid peroxides in LDL. FEBS Lett. 1991;286:152–154.
    1. Mackness M.I., Abott C.A., Arrol S., Durrington P.N. The role of HDL and lipid soluble antioxidant vitamins in inhibiting LDL oxidation. Biochem. J. 1993;294:829–835.
    1. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001;21:473–480.
    1. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 1996;7:69–76.
    1. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., Newton R.S., La Du B. Human serum paraoxonase is inactivated by oxidized LDL and reserved by antioxidants. Free Radic. Biol. Med. 1999;26:892–904.
    1. Ayub A., Mackness M.I., Arrol S., Mackness B., Patel J., Durrington P.N. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 1999;19:330–335.
    1. Mackness B., Davies G.K., Turkie W., Lee E., Roberts D.H., Hills E., Roberts C., Durrington P.N., Mackness M.I. Paraoxonase status in coronary artery disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 2001;21:1451–1457.
    1. Mackness B., Durrington P., McElduff P., John Y., Naheed A., Michael W., Michael M. Low paraoxonase activity predicts coronary events in the Caerphelly prospective study. Circulation. 2003;107:2775–2779.
    1. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284–287.
    1. Tward A., Xia Y.-R., Wang X.-P., Shi Y.-S., Park C., Castellani L.W., Lusis A.J., Shih D.M. Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice. Circulation. 2002;106:484–490.
    1. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., Rosenblat M. Human serum Paraoxonase Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON-1 esterase and peroxides-like activities. Circulation. 2000;101:2510–2517.
    1. Player J.R., Eza L.C., Bullen M.F., Evans D.A.P. Genetic polymorphism and inter-ethnic variability of plasma paraoxonase-1 activity. J. Med. Genet. 1976;13:337–342.
    1. Jayakumari N., Ambikakumari V., Balakrisgnan K.G., Iyer K.S. Distribution of cholesterol in HDL and its sub fractions in patients with coronary atherosclerotic heart disease. Ind. Heart J. 1993;45:265–268.
    1. Jayakumari N., Ambikakumari V., Balanrishnan K.G., Iyer K.S. Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis. 1992;94:183–190.
    1. Beuge J.A., Aust S.D. Thiobarbituric acid assay for lipid peroxides. Methods Enzymol. 1978;52:306–310.
    1. Desai D. Vitamin E analysis, methods for animal tissues. Methods Enzymol. 1984;105:138–147.
    1. Omaye S.T., Turnbull J.D., Sauberlich H.E. Selected methods for the determination of ascorbic acid in animal cells, tissues and fluids. Methods Enzymol. 1979;62:9–11.
    1. McCormick D.B. In: Vitamins: Methods for determination of vitamin A and β-carotene, in Textbook of Clinical Chemistry. N.W. Tietz., editor. W.B, Saunders company; West Washington square, Philadelphia: 1986. pp. 932–934.
    1. Lorenz K., Flatter B., Augustine E. Aryl esterase in serum: Elaboration and clinical application of fixed incubation method. Clin. Chem. 1979;25:1714–1720.
    1. Jarvick G.P., Hatsukami T.S., Carlson C., Richter R.J., Jampsa R., Brophy V.H., Margolin S., Rieder M., Nickerson D., Schellenberg G.D., Heagerty P.J., Furlong C.E. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 2003;23:1465–1471.
    1. Boemi M., Leviev I., Sirolla C., Pieri C., Marra M., James R.W. Serum paraoxonase is reduced in type 1 diabetes compared to non-diabetic, first-degree relatives: Influence of the ability of HDL to protect LDL from oxidation. Atherosclerosis. 2001;155:229–235.
    1. Agachen B., Yilmaz H., Karaali Z., Ishir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and lipids in urkish patients with non-insulin dependent diabetes mellitus. Cell Biochem. Funct. 2004;22:163–168.
    1. Kopprasch S., Pietzch J., Kuhlish E., Graessier J. Lack of association between serum paraoxonase activities and increased oxidation of LDL in impaired glucose tolerance and newly diagnosed diabetes mellitus. J. Clin. Endocrinol. Metab. 2003;88:1711–1716.
    1. Aviram M., Domfeld L., Rosenblat M., Volkova N., Kaplan M., Coleman R., Hayek T., Presser D., Fubrman B. Pomegranate juice consumption reduces oxidative stress, atherogenic modification of LDL and platelet aggregation: Studies in human and atherosclerotic apo-E deficient mice. Am. J. Clin. Nutr. 2000;71:1062–1076.
    1. van der Gaag M.S., van Tol A., Scheek L.M., James R.W., Urgert R., Schaafsma G., Hendriks H.F. Daily moderate alcohol consumption increases serum paraoxonase activity, a diet-controlled, randomized intervention study in middle-aged men. Atherosclerosis. 1999;147:405–410.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться